Quince Therapeutics (QNCX) Share-based Compensation (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Share-based Compensation of $9.3 million for Q1 2026, up 571.0% year-over-year from $1.4 million in Q1 2025, and up 82.17% quarter-over-quarter from $5.1 million in Q4 2025.
Quince Therapeutics (QNCX) Share-based Compensation (2018 - 2026) Analysis & Trends
Quince Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 571.0% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (up 50.0% YoY), while the FY2025 annual figure was $5.1 million, up 7.56% from the prior year.
- Share-based Compensation for Q1 2026 stood at $9.3 million, up from $5.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $9.3 million in Q1 2026, with the low at $9000.0 in Q3 2025.
- The 5-year median for Share-based Compensation is $1.5 million (2023), against an average of $2.9 million.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation slumped 97.37% in 2024, then soared 571.0% in 2026.
- Quince Therapeutics' Share-based Compensation stood at $1.6 million in 2022, then tumbled by 33.46% to $1.1 million in 2023, then jumped by 315.65% to $4.5 million in 2024, then rose by 13.09% to $5.1 million in 2025, then jumped by 82.17% to $9.3 million in 2026.
- Business Quant data shows QNCX's Share-based Compensation at $9.3 million in Q1 2026, $5.1 million in Q4 2025, and $9000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 10.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.30 Mn |
| Mar 31, 2026 | 9.30 Mn |
| Dec 31, 2025 | 5.11 Mn |
| Dec 31, 2025 | 5.11 Mn |
| Sep 30, 2025 | 9,000.00 |
| Sep 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |